We are live on ! Find out more
BBH icon

VanEck Biotech ETF

115 hedge funds and large institutions have $150M invested in VanEck Biotech ETF in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

0% more funds holding

Funds holding: 115115 (0)

1% less capital invested

Capital invested by funds: $152M → $150M (-$1.49M)

25% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 32

40.53% less ownership

Funds ownership: 78.34%37.81% (-41%)

Holders
115
Holders Change
Holders Change %
0%
% of All Funds
1.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
24
Reduced
32
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AF
126
Arrow Financial
New York
-$22.2K -125 Closed
JIP
127
Jaffetilchin Investment Partners
Florida
-$12.2K -69 Closed
VanEck Associates
128
VanEck Associates
New York
-$2K -13 Closed

BBH Hedge Fund Activity: Q4 2024 in Review

115 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2024, worth a combined $150M — down 0.98% from $152M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new BBH positions and 13 closed out — a net gain of 3 holders — while 24 added to existing stakes and 32 trimmed.

The largest buyer was TD Waterhouse Canada, opening a new position worth an estimated $10.7M. The largest seller was Citadel Advisors, cutting an estimated $2.7M.

  • 115 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $150M of VanEck Biotech ETF stock for Q4 2024, down 0.98% quarter-over-quarter.
  • 16 funds opened new VanEck Biotech ETF positions in Q4 2024 and 13 closed out, a net change of +3 holders.
  • The largest VanEck Biotech ETF buyer in Q4 2024 was TD Waterhouse Canada, an estimated $10.7M added.
  • The largest VanEck Biotech ETF seller in Q4 2024 was Citadel Advisors, an estimated $2.7M sold.

Based on aggregated 13F filings for Q4 2024.